Vermillion investor relations

Investors

2018 News

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
09/06/18Vermillion, Inc. Kicks Off Ovarian Cancer Awareness Month by Ringing the NASDAQ Closing Bell
AUSTIN, Texas, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (NASDAQ:VRML), a bioanalytical-based women’s health company focused on gynecologic disease, will ring the NASDAQ closing bell today.  “September is an opportunity for us to reach more women and raise awareness around ovarian cancer,” said Valerie Palmieri, President and CEO of Vermillion, Inc.   “We are working every day to change the status quo and lead the charge in better, and earlier, detection of ovarian cancer. Every 3... 
Printer Friendly Version
08/21/18Vermillion, Inc. Appoints Nancy Cocozza to its Board of Directors
Seasoned managed care leader with 30+ years of managed health experience AUSTIN, Texas, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (NASDAQ: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced the appointment of Nancy G. Cocozza to its Board of Directors.  Ms. Cocozza joins the Board effective August 17, 2018, and brings the Board composition to six members. “We warmly welcome Nancy to our Board,” said Valerie Palmieri, President and CEO... 
Printer Friendly Version
08/09/18Vermillion Reports Second Quarter 2018 Financial Results
Conference Call scheduled for today, August 9, 2018 at 4:30 p.m. ET AUSTIN, Texas, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2018. “We continue to make steady progress in our commercialization efforts and are pleased to see the fundamental building blocks in place.  With the sales force expansion, the hiring of Chris Goulart, S... 
Printer Friendly Version
07/18/18Vermillion to Report Second Quarter and Six Months Ended June 30, 2018 Financial Results on Thursday, August 9
AUSTIN, Texas, July 18, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that it will report financial results for the second quarter and six months ended June 30, 2018 on Thursday, August 9, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time. Thursday, August 9th @ 4:30pm Eastern Time Domestic:                   800-239-9838 International:              323-794-2551 Confe... 
Printer Friendly Version
06/13/18Vermillion Names Chris Goulart to Senior Vice President of Commercial Operations
Newly created position to focus on Company’s platform and portfolio growth AUSTIN, Texas, June 13, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (NASDAQ:VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that Mr. Chris Goulart has been appointed as Senior Vice President of Commercial Operations, a newly created position focusing on the Company’s growth operations.  “We warmly welcome Chris to the senior management team.  We believe Chris’s role is core to... 
Printer Friendly Version
05/14/18Vermillion Reports First Quarter 2017 Financial Results
Conference Call scheduled for today, May 14 at 4:30 p.m. ET AUSTIN, Texas, May 14, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (NASDAQ:VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the first quarter ended March 31, 2018. Valerie Palmieri, President and CEO, stated, “We commenced our commercialization strategy in the first quarter with the deployment of strategic sales representatives in key territories. We have seen strong si... 
Printer Friendly Version
05/03/18Vermillion to Report First Quarter 2018 Financial Results on Monday, May 14
AUSTIN, Texas, May 03, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its first quarter ended March 31, 2018 financial results on Monday, May 14, 2018, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time. Monday, May 14th @ 4:30pm Eastern Time Domestic:     800-239-9838 International:     ... 
Printer Friendly Version
04/26/18Vermillion Announces Recognition by and Publication in Two Top Physician Educational Resources
Article highlighting OVA1’s biomarker test published in the March 2018 issue of “UpToDate,” an evidence-based physician-authored publication OVA1 now included as part of a national Continuing Medical Education (CME) program AUSTIN, Texas, April 26, 2018 (GLOBE NEWSWIRE) -- ASPiRA LABs, a Vermillion company (NASDAQ:VRML), today announced that two top physician educational resources, UpToDate and the National Continuing Medical Education (CME) Program, have recognized the OVA1 (Multivariate... 
Printer Friendly Version
04/13/18Vermillion, Inc. Announces Pricing of $15 Million Concurrent Public Offerings of Common Stock and Preferred Stock
AUSTIN, Texas, April 13, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, today announced the pricing of the previously announced concurrent but separate underwritten public offerings of 10,000,000 shares of its common stock at a price to the public of $1.00 per share and 50,000 shares of its Series B Convertible Preferred Stock at a price to the public of $100.00 per share. Each share of Series B Convertible Preferred ... 
Printer Friendly Version
04/12/18Vermillion, Inc. Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
AUSTIN, Texas, April 12, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that it intends to offer shares of its common stock and convertible preferred stock in concurrent but separate underwritten public offerings. The convertible preferred stock is non-voting and convertible into shares of Vermillion, Inc. common stock automatically upon receipt of stockholder approval of the conversion. The offerings ... 
Printer Friendly Version
03/13/18Vermillion Reports Fourth Quarter and Fiscal Year 2017 Financial Results
Conference Call at 4:30 p.m. ET Today AUSTIN, Texas, March 13, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (NASDAQ:VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the fourth quarter and fiscal year ended December 31, 2017. Valerie Palmieri, President and CEO, stated, “2017 represented a watershed year for Vermillion. The Vermillion team delivered on our stated goals for 2017 by converting negative payer policies to positive poli... 
Printer Friendly Version
03/07/18Vermillion to Present at the 30th Annual ROTH Conference
AUSTIN, Texas, March 07, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer, are scheduled to participate in the 30th Annual ROTH Conference, taking place March 11-14 at the Ritz Carlton Hotel in Laguna Niguel, California.  Presentation Details Date:               Tuesday, March 13 Time:          ... 
Printer Friendly Version
02/28/18Vermillion to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Tuesday, March 13
AUSTIN, Texas, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its fourth quarter and fiscal year ended December 31, 2017 financial results on Tuesday, March 13, 2018, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time. Tuesday, March 13th @ 4:30 p.m. Eastern Time Domestic:   800-281-7973 International:   ... 
Printer Friendly Version
02/23/18Vermillion to Present at the 2018 BTIG Healthcare Conference
AUSTIN, Texas, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer, are scheduled to participate in BTIG’s 2018 Healthcare Conference from February 28, 2018 through March 1, 2018 in Snowbird, Utah.  BTIG’s annual conference will bring together more than 100 leading healthcare companies with ins... 
Printer Friendly Version
02/05/18Vermillion Announces the Grant of Two Ovarian Cancer Diagnostic Patents
AUSTIN, Texas, Feb. 5, 2018 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML) announced today that it has been granted two new US patents that significantly expand coverage for its core technologies, OVA1™ and Overa™. The first, US Patent No. 9,816,995, entitled "Biomarker for ovarian cancer CTAP3-related proteins," describes and claims panels of biomarkers associated with ovarian cancer. The second patent, US Patent No. 9,846,158, entitled "Predictive biomarkers for ovarian cancer... 
Printer Friendly Version
01/18/18Vermillion Announces Agreement with BlueCross BlueShield of Illinois
AUSTIN, Texas, Jan. 18, 2018 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and exclusive distributor of OVA1 (Multivariate Index Assay, or MIA), an ovarian cancer risk assessment test, today announced it has entered into an agreement with BlueCross BlueShield of Illinois. "ASPiRA Labs is excited to announce a contracted agreement for OVA1 with BCBS of Illinois, effective immediately," said Fred Ferrara, Chief Operating Officer of Vermillion... 
Printer Friendly Version

Share this page

share this page